Impact of environmental risk factors on gene & protein expression and their oxidative modification for cardiovascular health

During the last two decades, studies have shown that the physical environment, such as noise from road, aircraft or railway as well as air pollution, can facilitate the development of cardiovascular and metabolic diseases. We study the influence of aircraft noise exposure on cardiovascular and metabolic function in humans and model organisms using next generation sequencing and olink technology, and have identified oxidative stress and inflammation as central players in mediating vascular dysfunction. Our ongoing studies investigate the effects of aircraft noise in individuals with cardiovascular disease, as well as (non-) pharmacological mitigation strategies, the effects of particulate matter from air pollution on cardiovascular health, and the health effects of e-cigarette and shisha Vaping/smoking.

Positions held

Since 2008: Professor (W2) in Molecular Cardiology, University Medical Center Mainz
Since 2006: Head of Molecular Cardiology, University Medical Center Mainz
2000-2006: Postdoc, University of Konstanz and Exp. Cardiology, University Hospital Hamburg-Eppendorf and University Medical Center Mainz

Education

2000: PhD in Biological Chemistry, University of Konstanz
1997: Diploma in Chemistry, Biological Chemistry, University of Konstanz

Selected publications by Andreas Daiber

Steven S, Dib M, Hausding M, Kashani F, Oelze M, Kröller-Schön S, Hanf A, Daub S, Roohani S, Gramlich Y, Lutgens E, Schulz E, Becker C, Lackner KJ, Kleinert H, Knosalla C, Niesler B, Wild PS, Münzel T, Daiber A (2018) CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db miceCardiovasc Res 114(2):312-323 Link

Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Münzel T, Daiber A (2017) The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF ratsRedox Biol 13: 370-385 Link

Steven S, Jurk K, Kopp M, Kröller-Schön S, Mikhed Y, Schwierczek K, Roohani S, Kashani F, Oelze M, Klein T, Tokalov S, Danckwardt S, Strand S, Wenzel P, Münzel T, Daiber A (2017) Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic miceBritish journal of pharmacology 174: 1620-1632 Link

Münzel T, Gori T, Keaney JF Jr, Maack C, Daiber A (2015) Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implicationsEur Heart J 7;36(38):2555-64 Link

Oelze M, Kröller-Schön S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinßius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, Münzel T, Daiber A (2014) The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 17;9(11):e112394 Link

Research website